A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

NCT00994890 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

679

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Osteoarthritis, Knee
Osteoarthritis, Hip

Interventions

DRUG: Tanezumab 2.5 mg
DRUG: Tanezumab 5 mg
DRUG: Tanezumab 10 mg

Sponsor

Pfizer